Long-term investors fund Centaflow for a global launch

January 27, 2021

Centaflow A/S, a danish MedTech company, has announced the completion of an investment round totalling DKK 100 million from lead investor Haldor Topsøe Holding A/S together with the Danish pension fund PKA and a number of private investors.

The company is currently emerging from a ten-year initial research and development phase, with launch expected to commence in Denmark in 2022, followed by other Scandinavian countries, before a global roll-out will be pursued.

Centaflow is the first company to combine acoustic sensing with Artificial Intelligence to significantly improve the detection rate of Fetal Growth Restriction (FGR) – a global health concern.

FGR is a pregnancy complication which may result in emergencies and lifelong diseases, yet under the current standard of care, many FGR cases are not detected prior to birth. In several clinical studies, however, Centaflow has demonstrated the ability to non-invasively detect FGR, enabling healthcare professionals to take appropriate action.

Reflecting the public interest in addressing FGR, Centaflow has received keen interest from Danish universities and hospitals which has strengthened the research and development efforts.

Centaflow’s CEO, Søren Hofmeister, welcome the new investors, emphasising the importance of their long-term commitment to the company’s journey: “This investment will enable our strategy of contributing positively to the health and wellbeing of future generations.”

The investment transaction process was facilitated by Centaflow’s advisors Accura and Omera Consulting.

For further information, contact:

Søren Hofmeister

CEO, Centaflow A/S

+45 22 18 07 07